These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 2046082)

  • 1. Incidence of breakthrough bleeding during oral contraceptive therapy.
    Hill GA; Wheeler JM
    J Reprod Med; 1991 Apr; 36(4 Suppl):334-9. PubMed ID: 2046082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complexion changes in oral contraceptive users. Results from a phase IV multicenter trial evaluating the safety and efficacy of ethynodiol diacetate, 1 mg, with ethinyl estradiol, 35 micrograms.
    Wheeler JM; Malinak LR
    J Reprod Med; 1991 Apr; 36(4 Suppl):340-4. PubMed ID: 2046083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ethynodiol diacetate, 1 mg, with ethinyl estradiol, 35 micrograms, with an emphasis on contraceptive efficacy. A phase IV trial.
    Friedman AJ; Wheeler J
    J Reprod Med; 1991 Apr; 36(4 Suppl):328-33. PubMed ID: 2046081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of ovarian cyst formation in women taking ethynodiol diacetate, 1 mg, with ethinyl estradiol, 35 micrograms.
    Friedman AJ; Wheeler JM
    J Reprod Med; 1991 Apr; 36(4 Suppl):345-9. PubMed ID: 2046084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.
    Parsey KS; Pong A
    Contraception; 2000 Feb; 61(2):105-11. PubMed ID: 10802275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of a monophasic oral contraceptive containing 30 mcg ethinyl oestradiol and 150 mcg desogestrel (Marvelon).
    Ismail MT
    Malays J Reprod Health; 1994 Jun; 12(1):43-8. PubMed ID: 12320338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
    Benagiano G
    Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cycle control and side effects of a new combiphasic oral contraceptive regimen.
    Dieben TO; op ten Berg MT; Coelingh Bennink HJ
    Arzneimittelforschung; 1994 Jul; 44(7):877-9. PubMed ID: 7945527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tri-Regol and its application in gynecological practice].
    Marinov B; Kolarov G
    Akush Ginekol (Sofiia); 2000; 39(3):56-7. PubMed ID: 11188001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation.
    Serup J; Bostofte E; Larsen S; Westergaard J
    Acta Obstet Gynecol Scand; 1981; 60(2):203-6. PubMed ID: 7018165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical overview of a new triphasic contraceptive containing gestodene.
    Christie T
    Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new ultra-low-dose combination oral contraceptive.
    Woutersz TB
    J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
    Akerlund M
    Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
    Bilotta P; Favilli S
    Arzneimittelforschung; 1988 Jul; 38(7):932-4. PubMed ID: 2974702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC; Filho CI; Faggion D; Baracat EC
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing.
    Bruni V; Pontello V; Luisi S; Petraglia F
    Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):65-71. PubMed ID: 18358586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower hormone dosage with improved cycle control.
    Vree M
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():25-30; discussion 37-9. PubMed ID: 12659399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with hormonal contraceptives.
    Kulakov VI
    Acta Med Hung; 1986; 43(2):93-6. PubMed ID: 3588163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observations with a combined oral contraceptive (Rigevidon) containing minimum oestrogen dose.
    Karsay K
    Ther Hung; 1980; 28(1):17-20. PubMed ID: 7281074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.